Login/Sign Up
Borviz 3.5 Injection 1's belongs to a group of anti-cancer medicines used to treat adult patients with multiple myeloma and mantle cell lymphoma who have received at least one prior therapy. Multiple myeloma, also known as myeloma, is a type of bone marrow cancer it affects several areas of the body, such as the spine, skull, pelvis, and ribs. Mantle cell lymphoma (MCL) is a rare type of non-Hodgkin lymphoma (NHL). It develops when B-cells (also called B-lymphocytes) become abnormal. B-cells are white blood cells that fight infection.
Borviz 3.5 Injection 1's contains 'Bortezomibx' that works by interfering with how proteasomes work, which may cause cancer cells to die and may stop cancer from growing and eventually kills them.
Borviz 3.5 Injection 1's is prescribed by a doctor experienced in the use of medications to treat cancer. It is administered by a healthcare professional as an injection into your vein (intravenously or IV) or under your skin (subcutaneously or SC). Borviz 3.5 Injection 1's must not be administered into your spinal fluid (intrathecally). You may experience nausea, diarrhoea, thrombocytopenia (a low platelet count), neutropenia (low white blood cell count), peripheral neuropathy (nerves malfunction), fatigue, neuralgia, anaemia, leukopenia, constipation, vomiting, lymphopenia, rash, pyrexia, and anorexia. Most of these side effects of Borviz 3.5 Injection 1's do not require medical attention and gradually resolve over time. However, if the side effects are persistent, reach out to your doctor.
To treat your condition effectually, continue taking Borviz 3.5 Injection 1's for as long as your doctor has prescribed. Do not stop the Borviz 3.5 Injection 1's midway. Talk to your doctor before taking Borviz 3.5 Injection 1's if you have allergies or if you are suffering from peripheral neuropathy (nerves malfunction), hypotension, cardiac disorders, severe lung problems, pulmonary disorders, posterior reversible encephalopathy syndrome disorders, gastrointestinal disorders, thrombocytopenia (a low platelet count), neutropenia (low white blood cell count), tumour lysis syndrome (metabolic abnormalities that can occur as a complication during the treatment of cancer), hepatic disorders. Avoid taking Borviz 3.5 Injection 1's if you are pregnant or breastfeeding because this Borviz 3.5 Injection 1's can cause harmful effects on the unborn baby. Both women and men using this Borviz 3.5 Injection 1's should use birth control to avoid pregnancy.
Borviz 3.5 Injection 1's contains the active substance bortezomib, also-called ‘proteasome inhibitor. Proteasomes play an important role in controlling cell function and growth. By interfering with their function, thereby it can kill cancer cells. Borviz 3.5 Injection 1's is used to treat multiple myeloma (a cancer of the bone marrow) and mantle cell lymphoma (a type of cancer affecting the lymph nodes) in 18 years or older patients. It can be used alone or together with other medicines.
To treat your condition effectually, continue taking Borviz 3.5 Injection 1's for as long as your doctor has prescribed. Do not stop the Borviz 3.5 Injection 1's midway. Talk to your doctor before taking Borviz 3.5 Injection 1's if you have allergies or if you are suffering from peripheral neuropathy (nerves malfunction), hypotension, cardiac disorders, severe lung problems, pulmonary disorders, posterior reversible encephalopathy syndrome disorders, gastrointestinal disorders, thrombocytopenia (a low platelet count), neutropenia (low white blood cell count), tumour lysis syndrome (metabolic abnormalities that can occur as a complication during the treatment of cancer), hepatic disorders. And also, inform your doctor if you have diabetes because this medicine can affect your blood glucose levels. Your doctor may require close monitoring of your blood glucose levels and change your diabetes medicine dose while being treated with Borviz 3.5 Injection 1's. Avoid taking Borviz 3.5 Injection 1's if you are pregnant because this Borviz 3.5 Injection 1's can cause harmful effects on the unborn baby. Both women and men using this Borviz 3.5 Injection 1's should use birth control to avoid pregnancy and for at least six months following treatment. Do not breastfeed during treatment with Borviz 3.5 Injection 1's and four months after your final dose of Borviz 3.5 Injection 1's.
Drug-Drug Interactions: Borviz 3.5 Injection 1's interacts with antifungal medication (ketoconazole), HIV medication (ritonavir), antibiotic medication (rifampicin), epilepsy medications (carbamazepine, phenytoin or phenobarbital), depression medication (St. John’s Wort), and oral antidiabetics.
Drug-Food Interactions: No food interaction was found.
Drug-Disease Interactions: Inform your doctor before taking Borviz 3.5 Injection 1's; it requires close monitoring if you are suffering from peripheral neuropathy (nerves malfunction), hypotension, cardiac disorders, severe lung problems, pulmonary disorders, posterior reversible encephalopathy syndrome disorders, gastrointestinal disorders, thrombocytopenia (a low platelet count), neutropenia (low white blood cell count), tumour lysis syndrome (metabolic abnormalities that can occur as a complication during the treatment of cancer), and hepatic disorders.
Multiple myeloma, also known as myeloma, is a type of bone marrow cancer it affects several areas of the body, such as the spine, skull, pelvis, and ribs.
Mantle cell lymphoma (MCL) is a rare type of non-Hodgkin lymphoma (NHL). It develops when B-cells (also called B-lymphocytes) become abnormal. B-cells are white blood cells that fight infection.
Cancer is a condition where cells in a specific body part grow and reproduce uncontrollably. The cancerous cells can invade and destroy surrounding healthy tissue, including organs.
About Borviz 3.5 Injection 1's
Borviz 3.5 Injection 1's belongs to a group of anti-cancer medicines used to treat adult patients with multiple myeloma and mantle cell lymphoma who have received at least one prior therapy. Multiple myeloma, also known as myeloma, is a type of bone marrow cancer it affects several areas of the body, such as the spine, skull, pelvis, and ribs. Mantle cell lymphoma (MCL) is a rare type of non-Hodgkin lymphoma (NHL). It develops when B-cells (also called B-lymphocytes) become abnormal. B-cells are white blood cells that fight infection.
Borviz 3.5 Injection 1's contains 'Bortezomibx' that works by interfering with how proteasomes work, which may cause cancer cells to die and may stop cancer from growing and eventually kills them.
Borviz 3.5 Injection 1's is prescribed by a doctor experienced in the use of medications to treat cancer. It is administered by a healthcare professional as an injection into your vein (intravenously or IV) or under your skin (subcutaneously or SC). Borviz 3.5 Injection 1's must not be administered into your spinal fluid (intrathecally). You may experience nausea, diarrhoea, thrombocytopenia (a low platelet count), neutropenia (low white blood cell count), peripheral neuropathy (nerves malfunction), fatigue, neuralgia, anaemia, leukopenia, constipation, vomiting, lymphopenia, rash, pyrexia, and anorexia. Most of these side effects of Borviz 3.5 Injection 1's do not require medical attention and gradually resolve over time. However, if the side effects are persistent, reach out to your doctor.
To treat your condition effectually, continue taking Borviz 3.5 Injection 1's for as long as your doctor has prescribed. Do not stop the Borviz 3.5 Injection 1's midway. Talk to your doctor before taking Borviz 3.5 Injection 1's if you have allergies or if you are suffering from peripheral neuropathy (nerves malfunction), hypotension, cardiac disorders, severe lung problems, pulmonary disorders, posterior reversible encephalopathy syndrome disorders, gastrointestinal disorders, thrombocytopenia (a low platelet count), neutropenia (low white blood cell count), tumour lysis syndrome (metabolic abnormalities that can occur as a complication during the treatment of cancer), hepatic disorders. Avoid taking Borviz 3.5 Injection 1's if you are pregnant or breastfeeding because this Borviz 3.5 Injection 1's can cause harmful effects on the unborn baby. Both women and men using this Borviz 3.5 Injection 1's should use birth control to avoid pregnancy.
₹5121.23*
MRP ₹6245.4
18% off
₹5308.59*
MRP ₹6245.4
15% CB
₹936.81 cashback(15%)
Free Delivery
With Circle membership
(Inclusive of all Taxes)
This offer price is valid on orders above ₹800. Apply coupon PHARMA10/PHARMA18 (excluding restricted items)
Online payment accepted
Provide Delivery Location
Whats That
Online payment accepted
Product Substitutes
Uses of Borviz 3.5 Injection 1's
Medicinal Benefits
Borviz 3.5 Injection 1's contains the active substance bortezomib, also-called ‘proteasome inhibitor. Proteasomes play an important role in controlling cell function and growth. By interfering with their function, thereby it can kill cancer cells. Borviz 3.5 Injection 1's is used to treat multiple myeloma (a cancer of the bone marrow) and mantle cell lymphoma (a type of cancer affecting the lymph nodes) in 18 years or older patients. It can be used alone or together with other medicines.
Side Effects of Borviz 3.5 Injection 1's
Directions for Use
Storage
Drug Warnings
To treat your condition effectually, continue taking Borviz 3.5 Injection 1's for as long as your doctor has prescribed. Do not stop the Borviz 3.5 Injection 1's midway. Talk to your doctor before taking Borviz 3.5 Injection 1's if you have allergies or if you are suffering from peripheral neuropathy (nerves malfunction), hypotension, cardiac disorders, severe lung problems, pulmonary disorders, posterior reversible encephalopathy syndrome disorders, gastrointestinal disorders, thrombocytopenia (a low platelet count), neutropenia (low white blood cell count), tumour lysis syndrome (metabolic abnormalities that can occur as a complication during the treatment of cancer), hepatic disorders. And also, inform your doctor if you have diabetes because this medicine can affect your blood glucose levels. Your doctor may require close monitoring of your blood glucose levels and change your diabetes medicine dose while being treated with Borviz 3.5 Injection 1's. Avoid taking Borviz 3.5 Injection 1's if you are pregnant because this Borviz 3.5 Injection 1's can cause harmful effects on the unborn baby. Both women and men using this Borviz 3.5 Injection 1's should use birth control to avoid pregnancy and for at least six months following treatment. Do not breastfeed during treatment with Borviz 3.5 Injection 1's and four months after your final dose of Borviz 3.5 Injection 1's.
Therapeutic Class
Drug-Drug Interactions Checker List
Diet & Lifestyle Advise
Habit Forming
Special Advise
Disease/Condition Glossary
Multiple myeloma, also known as myeloma, is a type of bone marrow cancer it affects several areas of the body, such as the spine, skull, pelvis, and ribs.
Mantle cell lymphoma (MCL) is a rare type of non-Hodgkin lymphoma (NHL). It develops when B-cells (also called B-lymphocytes) become abnormal. B-cells are white blood cells that fight infection.
Cancer is a condition where cells in a specific body part grow and reproduce uncontrollably. The cancerous cells can invade and destroy surrounding healthy tissue, including organs.